Information For Investors

Medika Natura is an innovative producer and marketer of botanical bio-active ingredients of Malaysian and Southeast Asian origin. Our mission is to produce scientifically proven, novel botanical ingredients for the pharmaceutical, nutraceutical and cosmeceutical uses.

Medika Natura became the first Malaysian company to ever receive clearance from the United States Food and Drug Administration (USFDA) for a product, when the USFDA certified our proprietary product, SKF7™, as a New Dietary Ingredient (NDIN) in 2020. SKF7™ is also due to receive clearance from the European Food Safety Authority (EFSA) as a Novel Food in 2021.

Derived from botanical bio-active compounds, SKF7™ is a safe, efficacious pharma-grade solution targeting obesity. Proven safe and devoid of significant allergic risk, SKF7™ is currently undergoing pre-clinical studies into its efficacy with regards to treating diabetes, cancer, and its anti-viral properties in combating Covid-19.

SKF7™ is a standardized extract of Labisia pumila, also known in Malaysia as Kacip Fatimah. We have begun generating pre-revenues through the sale of SKF7™ in selected pharmacies in Kuala Lumpur, Malaysia, under the brand name Labeesity®, and we plan to bring the product to the market through carefully selected doctors and pharmacies in Indonesia and Singapore.

In line with our expansion beyond Southeast Asia, we have finalized and obtained approvals for SKF7™’s product label claims for North American markets, enabling SKF7™ to be available in the United States via Amazon in 2021. Registration is also underway in Canada, the European Union (EU), United Kingdom (UK), China, Taiwan, Australia, Korea and United Arab Emirates (UAE), with plans in place to progressively add countries to this list as we move forward.

As part of the process of obtaining approval for SKF7™ to be classified and marketed as a botanical drug, we launched a multi-centre Phase 2 dose-ranging study of SKF7™ in 2020. This randomized double-blind placebo-controlled study involving over 300 subjects examines the efficacy of SKF7™ as an anti-obesity treatment. Obesity is a global health crisis, linked to increased risk of death from cardiovascular disease, diabetes, cancer, and even Covid-19. Our ongoing research and the human clinical study of SKF7™ may have a crucial role to play in combating the global obesity crisis.

Our business and clinical strategies are geared towards realizing our goal of making SKF7™ available in global markets, and positioning Medika Natura for listing on the Hong Kong Stock Exchange and/or NASDAQ in 2023.

Funding and
Use of Proceeds

To date, Medika Natura has secured limited funding from the Malaysian government and its agencies to conduct research and development and begin the process of commercialisation for SKF7™ in selected international markets. In early 2020, we began raising additional funds from private individuals and continue to seek to raise equity investments from strategic investors globally.

Funding will be used to establish GAP-certified herbal plantations and a GMP-certified herbal extraction facility, as well as for clinical trials, product registrations, manufacturing support and market expansion into selected countries of interest through strategic partnership arrangements.

This initiative is part of our strategic plan for listing on the Hong Kong Stock Exchange and/or NASDAQ in 2023.

Key Executives

Abdul Razak Mohd Isa, Chief Executive Officer and Co-founder

Mustadza Muhamad, Chief Operating Officer and Co-founder

Dato’ Amin Rafie Othman, Director, Corporate Affairs

Datuk Ali Abdul Kadir, Chairman, Board of Advisors

Prof. Dr. Zhari Ismail, Scientific Advisor

Looking to invest? Contact us.

 Complete the form and a representative from Medika Natura will be in contact.